Liraglutide and sibutramine: similarities and differences in pharmacotherapy of obesity
AbstractThe centrally acting anti-obesity drugs currently registered in the Russian Federation include liraglutide 3.0 mg (Saxenda®, Enligria®) and a number of sibutramine-containing drugs, including Reduxin®, Reduxin Forte®. This literature review compares data on the mechanisms of action of these drugs and their effect on homeostatic and hedonistic regulation of body weight, production of glucagon-like peptide‑1, and gut microbiota. Information is provided on the effects of these drugs on major metabolic parameters, eating behavior, and quality of life. It has been shown that, despite the significant difference in the receptor mechanisms of action, liraglutide and sibutramine-containing drugs have a similar spectrum of influence on key links in energy balance regulation and have comparable metabolic effects. Pharmacodynamic features against the background of a complex of similar metabolic effects make it possible to use the above drugs both for sequential therapy and for personification of obesity therapy in general. Mutual replacement of drugs is possible if long-term therapy is necessary, if adverse events or intolerance occur in patients without contraindications.
Keywords:obesity; sibutramine; Reduxin®; liraglutide; Enligria®
Funding. The study was supported by PROMOMED DM.
Conflict of interest. Professor Tatiana I. Romantsova is a member of the expert councils and advisory committees for the drugs Saxenda®, Reduxin®, Reduxin Forte®, Enligria®; gives lectures in collaboration with Novo Nordisk and PROMOMED DM; took part in observational studies and clinical trials supported by PROMOMED DM.
For citation: Romantsova T.I. Liraglutide and sibutramine: similarities and differences in pharmacotherapy of obesity. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2023; 12 (4): 117–31. DOI: https://doi.org/10.33029/2304-9529-2023-12-4-117-31 (in Russian)
References
1. Bray G.A., Kim K.K., Wilding J.P.H., et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017; 18 (7): 715–23. DOI: https://doi.org/10.1111/obr.12551
2. Magkos F., Fraterrigo G., Yoshino J., et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016; 23: 1–11. DOI: https://doi.org/10.1016/j.cmet.2016.02.005
3. McGuire M.T., Wing R.R., Hill J.O. The prevalence of weight loss maintenance among American adults. Int J Obes Relat Metab Disord. 1999; 23: 1314–9. DOI: https://doi.org/10.1038/sj.ijo.0801075
4. Secher A., Jelsing J., Baquero A.F., et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014; 124 (10): 4473–88. DOI: https://doi.org/10.1172/JCI75276
5. Drucker D.J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022; 57: 101351. DOI: https://doi.org/10.1016/j.molmet.2021.101351
6. Baggio L.L., Drucker D.J. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014; 124 (10): 4223–6. DOI: https://doi.org/10.1172/JCI78371
7. Nonogaki K. The Regulatory role of the central and peripheral serotonin network on feeding signals in metabolic diseases. Int J Mol Sci. 2022; 23 (3): 1600. DOI: https://doi.org/10.3390/ijms23031600
8. Anderberg R.H., Richard J.E., Eerola K., et al. Glucagon-like peptide 1 and its analogs act in the dorsal raphe and modulate central serotonin to reduce appetite and body weight. Diabetes. 2017; 66 (4): 1062–73. DOI: https://doi.org/10.2337/db16-0755
9. Khorassani F.E., Misher A., Garris S. Past and present of antiobesity agents: focus on monoamine modulators. Am J Health Syst Pharm. 2015; 72 (9): 697–706. DOI: https://doi.org/10.2146/ajhp140034
10. Vardanyan G.S., Harutyunyan H.S., Aghajanov M.I., Vardanyan R.S. Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects. Future Med Chem. 2020; 12 (20): 1865–84. DOI: https://doi.org/10.4155/fmc-2019-0361
11. Bello N.T., Liang N.C. The use of serotonergic drugs to treat obesity – is there any hope? Drug Des Devel Ther. 2011; 5: 95–109. DOI: https://doi.org/10.2147/DDDT.S11859
12. Burke L.K., Heisler L.K. 5-hydroxytryptamine medications for the treatment of obesity. J Neuroendocrinol. 2015; 27 (6): 389–98. DOI: https://doi.org/10.1111/jne.12287
13. Kintscher U. Reuptake inhibitors of dopamine, noradrenaline, and serotonin. In: Appetite Control. Springer, 2012: 339–47. DOI: https://doi.org/10.1007/978-3-642-24716-3_15
14. Wallace C.W., Fordahl S.C. Obesity and dietary fat influence dopamine neurotransmission: exploring the convergence of metabolic state, physiological stress, and inflammation on dopaminergic control of food intake. Nutr Res Rev. 2022; 35 (2): 236–51. DOI: https://doi.org/10.1017/S0954422421000196
15. Araujo R.J., Martel F. Sibutramine effects on central mechanisms regulating energy homeostasis. Curr Neuropharmacol. 2012; 10 (1): 49–52. DOI: https://doi.org/10.2174/157015912799362788
16. Jackson H.C., Bearham M.C., Hutchins L.J., Mazurkiewicz S.E., Needham A.M., Heal D.J. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol. 1997; 121 (8): 1613–8. DOI: https://doi.org/10.1038/sj.bjp.0701311
17. Grignaschi G., Fanelli E., Scagnol I., Samanin R. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats. Br J Pharmacol. 1999; 127 (5): 1190–4. DOI: https://doi.org/10.1038/sj.bjp.0702633
18. Yanovski S.Z., Yanovski J.A. Obesity. N Engl J Med. 2002; 346 (8): 591–602. DOI: https://doi.org/10.1056/NEJMra012586
19. Williams D.L. The diverse effects of brain glucagon-like peptide 1 receptors on ingestive behaviour. Br J Pharmacol. 2022; 179 (4): 571–83. DOI: https://doi.org/10.1111/bph.15535
20. Farr O.M., Sofopoulos M., Tsoukas M.A., et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016; 59 (5): 954–6.
21. Yee D.M., Leng X., Shenhav A., Braver T.S. Aversive motivation and cognitive control. Neurosci Biobehav Rev. 2022; 133: 104493. DOI: https://doi.org/10.1016/j.neubiorev.2021.12.016
22. Talbot P.S., Bradley S., Clarke C.P., et al. brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using 11C-DASB in healthy humans. Neuropsychopharmacology. 2009; 35 (3): 741–51. DOI: https://doi.org/10.1038/npp.2009.182
23. Fletcher P.C., Napolitano A., Skeggs A., et al. Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. J Neurosci. 2010; 30 (43): 14 346–55. DOI: https://doi.org/10.1523/jneurosci.3323-10.2010
24. Kuznetsova P.I., Tanashyan M.M., Romantsova T.I., Tsvetkova E.S., Kremneva E.I., Logvinova O.V., Troshina E.A.. Functional brain MRI in the setting of drug correction of obesity. Ozhirenie i metabolism [Obesity and Metabolism]. 2022; 19 (1): 74–82. DOI: https://doi.org/10.14341/omet12810 (in Russian)
25. Hansen H.H., Perens J., Roostalu U., Skytte J.L., Salinas C.G., Barkholt P., et al. Whole-brain activation signatures of weight-lowering drugs. Mol Metab. 2021; 47: 101171. DOI: https://doi.org/10.1016/j.molmet.2021.101171
26. Kanoski S.E., Hayes M.R., Skibicka K.P. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016; 310 (10): 885–95.
27. Brierley D.I., Holt M.K., Singh A., et al. Central and peripheral GLP-1 systems independently suppress eating. Nat Metab. 2021; 3 (2): 258–73. DOI: https://doi.org/10.1038/s42255-021-00344-4
28. Volkova G.E. Eating behavior, emotional and personal characteristics and mediators of energy metabolism in obese patients. Diss. Moscow, 2011: 22 p. (in Russian)
29. D’Agostino G., Lyons D., Cristiano C., et al. Nucleus of the solitary tract serotonin 5-HT2C receptors modulate food intake. Cell Metab. 2018; 28 (4): 619–30.e5. DOI: https://doi.org/10.1016/j.cmet.2018.07.017
30. Wagner S., Brierley D.I., Leeson-Payne A., et al. Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression. Mol Metab. 2023; 68: 101665. DOI: https://doi.org/10.1016/j.molmet.2022.101665
31. Frassetto S.S., Della Santa Rubio A., Lopes J.J., et al. Locomotor and peripheral effects of sibutramine modulated by 5-HT2 receptors. Can J Physiol Pharmacol. 2006; 84 (12): 1239–44. DOI: https://doi.org/10.1139/y06-082
32. Xu J., Chen J.D. Peripheral mechanisms of sibutramine involving proximal gastric motility in dogs. Obesity (Silver Spring). 2006; 14 (8): 1363–70. DOI: https://doi.org/10.1038/oby.2006.154 PMID: 16988078.
33. van Can J., Sloth B., Jensen C.B., et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014; 38 (6): 784–93. DOI: https://doi.org/10.1038/ijo.2013.162
34. Vazquez Roque M.I., Camilleri M., Clark M.M., et al. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol. 2007; 5 (7): 829–37. DOI: https://doi.org/10.1016/j.cgh.2007.02.037
35. Angelidi A.M., Belanger M.J., Kokkinos A., et al. Novel noninvasive approaches to the treatment of obesity: from pharmacotherapy to gene therapy. Endocr Rev. 2022; 43 (3): 507–57. DOI: https://doi.org/10.1210/endrev/bnab034
36. Moreira G.V., Azevedo F.F., Ribeiro L.M., Santos A., Guadagnini D., Gama P., et al. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J Nutr Biochem. 2018; 62: 143–54. DOI: https://doi.org/10.1016/j.jnutbio.2018.07.009
37. Zhao L., Qiu Y., Zhang P., et al. Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet. Front Nutr. 2022; 9: 1048693. DOI: https://doi.org/10.3389/fnut.2022.1048693
38. Raineri S., Sherriff J.A., Thompson K.S.J., et al. Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats. BMC Microbiol. 2022; 22 (1): 91. DOI: https://doi.org/10.1186/s12866-022-02494-1
39. Connoley I.P., Liu Y.-L., Frost I., Reckless I.P., Heal D.J., Stock M.J. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol. 1999; 126 (6): 1487–95. DOI: https://doi.org/10.1038/sj.bjp.070244694-1 PMID: 35392807; PMCID: PMC 8988407.
40. Filippatos T.D., Kiortsis D.N., Liberopoulos E.N., Mikhailidis D.P., Elisaf M.S. A review of the metabolic effects of sibutramine. Curr Med Res Opin. 2005; 21 (3): 457–66. DOI: https://doi.org/10.1185/030079905x38132
41. Ametov A.S. Report on the SPRING program. Effective treatment of obesity is the way to combat the diabetes mellitus epidemic. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2013; (2): 12–8. (in Russian)
42. Dedov I.I., Melnichenko G.A., Romantsova T.I The strategy of obesity management: the results of All-Russian observational program “Primavera”. Ozhirenie i metabolism [Obesity and Metabolism]. 2016; 13 (1): 36–44. DOI: https://doi.org/10.14341/omet2016136-44 (in Russian)
43. Davies M.J., Bergenstal R., Bode B., et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015; 314: 687–99.
44. Wadden T.A., Hollander P., Klein S., et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013; 37 (11): 1443–51. DOI: https://doi.org/10.1038/ijo.2013.120
45. Matveev G.A., Golikova T.I., Vasileva A.A., Vasilieva E.V., Babenko A.Y., Shlyakhto E.V. Comparison of the effects of liraglutide and sibutramine in obese patients. Ozhirenie i metabolism [Obesity and Metabolism]. 2021; 18 (2): 218–28. DOI: https://doi.org/10.14341/omet12498 (in Russian)
46. Hansen G., Jelsing J., Vrang N. Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats. Acta Pharmacol Sin. 2012; 33 (2): 194–200. DOI: https://doi.org/10.1038/aps.2011.168
47. James W.P., Astrup A., Finer N., Hilsted J., Kopelman P., Rössner S., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000; 356 (9248): 2119–25. DOI: https://doi.org/10.1016/s0140-6736(00)03491-7 PMID: 11191537.
48. Butrova S.A. Sibutramine in the treatment of obesity (based on materials from the congress “Man and Medicine”. Moscow, April 2001).RMZh [Russian Medical Journal]. 2001; (9): 348. (in Russian)
49. Wharton S., Jacobsen P., Arrone L. Early responders to liraglutide 3.0 mg as adjunct to diet and excercise from the SCALE Maintenance trial. In: Oral Presentation Number RS 3:3. ECO. 2017.
50. le Roux C.W., Astrup A., Fujioka K., et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized double-blind trial. Lancet. 2017; 389 (10 077): 1399–409. DOI: https://doi.org/10.1016/s0140-6736(17)30069-7
51. Norris S.L., Zhang X., Avenell A., Gregg E., Schmid C.H., Kim C., et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med. 2004; 164 (13): 1395–404. DOI: https://doi.org/10.1001/archinte.164.13.1395 PMID: 15249348.
52. Dorofeeva L.G., Koteshkova O.M., Antsiferov M.B. Sibutramine in the treatment of obesity in patients with type 2 diabetes mellitus. Farmateka [Pharmateca]. 2006; 3 (118). (in Russian)
53. Kolotkin R.L., Gabriel Smolarz B., Meincke H.H., Fujioka K. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Clin Obes. 2018; 8 (1): 1–10. DOI: https://doi.org/10.1111/cob.12226
54. van Ruiten C.C., Ten Kulve J.S., van Bloemendaal L., Nieuwdorp M., Veltman D.J., Ijzerman R.G. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology. 2022; 137: 105667. DOI: https://doi.org/10.1016/j.psyneuen.2022.105667
55. Volkova G.E., Romantsova T.I., Voznesenskaya T.G., Roik O.V. Eating behavior in obese patients. Ozhirenie i metabolism [Obesity and Metabolism]. 2007; 4 (2): 17–21. DOI: https://doi.org/10.14341/2071-8713-5158 (in Russian)
56. Matveev G.А., Babenko A. Yu. Efficacy of sibutramine in different types of eating behavior in obese patients. Meditsinskiy sovet [Medical Council]. 2022; (10): 140–7. DOI: https://doi.org/10.21518/2079-701X-2022-16-10-140-147 (in Russian)
57. Logvinova O.V., Troshina E.A. Effect of liraglutide 3.0 mg on eating behavior in patients with obesity. Meditsinskiy sovet [Medical Council]. 2021; (7): 156–64. DOI: https://doi.org/10.21518/2079-701X-2021-7-156-164
58. Yerevanian A., Soukas A.A. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019; 8 (2): 156–64. DOI: https://doi.org/10.1007/s13679-019-00335-3 PMID: 30874963; PMCID: PMC 6520185.
59. Dedov I.I., Romantsova T.I., Shestakova M.V. Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program “AURORA”. Ozhirenie i metabolism [Obesity and Metabolism]. 2018; 15 (4): 48–58. DOI: https://doi.org/10.14341/omet10076 (in Russian)
60. Demidova T. Yu., Izmailova M.Y., Ushakova S.E., Zaslavskaya K.Y., Odegova A.A., Popova V.V., Nevretdinova M.E., Bely P.A. Evaluation of weight reduction efficacy and safety of sibutramin-containing drugs in patients with alimentary obesity. Farmatsiya i farmakologiya [Pharmacy and Pharmacology]. 2022; 10 (3): 289–304. DOI: https://doi.org/10.19163/2307-9266-2022-10-3-289-304
61. Tronieri J.S., Wadden T.A., Walsh O.A., et al. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: a randomized placebo-controlled pilot trial. Metabolism. 2019; 96: 83–91. DOI: https://doi.org/10.1016/j.metabol.2019.03.005
62. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res. 2000; 8 (6): 431–7. DOI: https://doi.org/10.1038/oby.2000.53
63. Sari R., Balci M.K., Cakir M., et al. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res. 2004; 30 (2): 159–67. DOI: https://doi.org/10.1081/erc-200027356